Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in <i>FLT3</i>-ITD AML with concurrent epigenetic mutations

User: Guest

Title:: Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations
Document type:: Zeitschriftenaufsatz
Author(s):: Garz, Anne-Kathrin; Wolf, Saskia; Grath, Sonja; Gaidzik, Verena; Habringer, Stefan; Vick, Binje; Rudelius, Martina; Ziegenhain, Christoph; Herold, Sylvia; Weickert, Marie-Theresa; Smets, Martha; Peschel, Christian; Oostendorp, Robert A.J.; Bultmann, Sebastian; Jeremias, Irmela; Thiede, Christian; Döhner, Konstanze; Keller, Ulrich; Götze, Katharina S.
Journal title:: Oncotarget
Year:: 2017
Journal volume:: 8
Journal issue:: 65
Fulltext / DOI:: doi:10.18632/oncotarget.21877
Publisher:: Impact Journals, LLC
E-ISSN:: 1949-2553
Date of publication:: 19.10.2017
BibTeX

Occurrences:

Azacitidine combined with the selective FLT3 kinase inhibitor crenolanib disrupts stromal protection and inhibits expansion of residual leukemia-initiating cells in FLT3-ITD AML with concurrent epigenetic mutations